

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥(集團)股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the “Announcement in Relation to the Approval for Drug Registration of a Subsidiary” published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the PRC

30 October 2024

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Pan Donghui and Mr. Chen Yuqing; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* *for identification purposes only*

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Announcement in Relation to the Approval for Drug Registration of a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement, or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Yaopharma Co., Ltd.* (重慶藥友製藥有限責任公司), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥(集團)股份有限公司) (the “**Company**” and, together with its subsidiaries/units, the “**Group**”), recently received the marketing registration approval from the National Medical Products Administration for Roxatidine Acetate Hydrochloride for Injection (the “**New Drug**”).

II. General Information of the New Drug

Generic Name: Roxatidine Acetate Hydrochloride for Injection

Dosage Form: Injection

Strength: 75mg

Registration Category: Chemicals Category 3

Marketing Authorization Holder/ Pharmaceutical Manufacturer: Yaopharma Co., Ltd.* (重慶藥友製藥有限責任公司)

Drug Approval Number: Guo Yao Zhun Zi H20249114

III. Research and Marketing Progress of the New Drug

The New Drug is a chemical drug independently developed by the Group, which is indicated for low-risk patients with upper gastrointestinal bleeding (caused by

gastroduodenal ulcers, acute stress ulcers, hemorrhagic gastritis, etc.).

As of September 2024, the Group has invested approximately RMB3.31 million (unaudited) in total in the research and development of the New Drug at the current stage.

According to the latest data from IQVIA CHPA¹, in 2023, the sales of Roxatidine Acetate Hydrochloride for Injection approved for marketing in China (excluding Hong Kong, Macao, and Taiwan regions) was approximately RMB943 million.

IV. Impact on the Listed Company and Risk Warning

The approval for marketing registration of the New Drug will bring more options for the medication for patients with upper gastrointestinal bleeding and will enrich the product line of the Group. It is expected that the approval of the New Drug will not have a material impact on the Group's results at this stage.

Due to the characteristics of the pharmaceutical products industry, the specific sales performance of pharmaceutical products after launch may be affected by factors including, but not limited to, the demand for medication, market competition and sales channels, and is subject to considerable uncertainty. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

30 October 2024

¹ provided by IQVIA, a provider of professional medical and health information and strategic consultation service in the world; IQVIA CHPA data represents the drug sales market of hospitals with more than 100 beds in China, the actual sales of different drugs may vary from the IQVIA CHPA data to varying degrees due to their different sales channels.